Spotlight: the story behind the ADHD prescribing surge

In this episode of The PJ Pod, we investigate how increased prescribing for attention deficit hyperactivity disorder is affecting NHS services.

In June 2023, The Pharmaceutical Journal revealed that the number of adults in England prescribed medicines for attention deficit hyperactivity disorder (ADHD) has more than doubled since January 2020.

The increase, which was particularly pronounced in females, has been largely fuelled by increasingly frequent opportunities for adults to pinpoint the symptoms of ADHD in themselves, either as a result of COVID-19 lockdowns or owing to growing awareness of famous faces recounting their own ADHD diagnoses.

While the added demand is already seeing patients wait years for treatment from over-extended NHS services for the condition, experts say ADHD is still vastly underdiagnosed.

In this episode of The PJ Pod, executive editor Carolyn Wickware and senior features editor Dawn Connelly take a closer look at the prescribing data and talk about what the increase in diagnoses means for patients and the NHS going forward.

For a full breakdown of the data discussed in this episode, read our special report, charting the rise in ADHD prescribing.

More information can be found here on offering support to manage ADHD, as well as information on its characteristics and diagnosis.

This episode was produced by Geoff Marsh.

Want to hear more from The PJ Pod? Follow us on SpotifyGoogle PodcastsApple Podcasts or other popular podcast platforms to listen to our latest episodes. 

Last updated
The Pharmaceutical Journal, PJ, July 2023, Vol 311, No 7975;311(7975)::DOI:10.1211/PJ.2023.1.192472

    Please leave a comment 

    You may also be interested in